Affiliations 

  • 1 QST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
  • 2 School of Radiation Medicine and Protection, Medical College, Soochow University, Suzhou, China
  • 3 Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • 4 Institut Kanser Negara, Putrajaya, Malaysia
  • 5 Department of Radiation Oncology, St Luke's Medical Center, Quezon City, The Philippines
  • 6 Department of Obstetrics and Gynecology, Jose R. Reyes Memorial Medical Center, FEU-NRMF Institute of Medicine, Metro Manila, Philippines
  • 7 Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 8 Department of Radiation Oncology, United Hospital Limited, Dhaka, Bangladesh
  • 9 Department of Clinical and Radiation Oncology, Ministry of Health of the Republic of Kazakhstan, Semey Medical University, Semey, Kazakhstan
  • 10 Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
  • 11 Department of Radiation Oncology, National Cancer Center of Mongolia, Ulaanbaatar, Mongolia
  • 12 Department of General Radiation Oncology, National Cancer Hospital, Hanoi, Vietnam
  • 13 Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
  • 14 Quantum Medical Science Directorate, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
  • 15 Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan
J Radiat Res, 2020 Jul 06;61(4):608-615.
PMID: 32367130 DOI: 10.1093/jrr/rraa025

Abstract

3D image-guided brachytherapy (3D-IGBT) has become a standard therapy for cervical cancer. However, the use of 3D-IGBT is limited in East and Southeast Asia. This study aimed to clarify the current usage patterns of 3D-IGBT for cervical cancer in East and Southeast Asia. A questionnaire-based survey was performed in 11 countries within the framework of the Forum for Nuclear Cooperation in Asia. The questionnaire collected the treatment information of patients with cervical cancer who underwent 3D-IGBT. The cumulative external beam radiotherapy and 3D-IGBT doses were summarized and normalized to a biological equivalent dose of 2 Gy per fraction (EQD2) using a linear-quadratic model. Of the 11 institutions representing the participating countries, six (55%) responded to the questionnaire. Overall, data of 36 patients were collected from the six institutions. Twenty-one patients underwent whole-pelvic irradiation and 15 underwent whole-pelvic irradiation with central shielding. Patients received a median of four treatment sessions of 3D-IGBT (range, 2-6). All 3D-IGBT sessions were computed tomography (CT)-based and not magnetic resonance image-based. The median doses to the high-risk clinical target volume D90, bladder D2cc, rectum D2cc and sigmoid colon D2cc were 80.9 Gy EQD2 (range, 58.9-105.9), 77.7 Gy EQD2 (range, 56.9-99.1), 68.0 Gy EQD2 (range, 48.6-90.7) and 62.0 Gy EQD2 (range, 39.6-83.7), respectively. This study elucidated the current patterns of 3D-IGBT for the treatment of cervical cancer in East and Southeast Asia. The results indicate the feasibility of observational studies of CT-based 3D-IGBT for cervical cancer in these countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.